Please use this identifier to cite or link to this item:
|Title:||Role of Cyclooxygenase-2 in Tumor Progression and Immune Regulation in Lung Cancer|
|Keywords:||Cyclooxygenase (COX);Non-small cell lung carcinoma (NSCLC);Non-steroidal anti-inflammatory drugs (NSAIDs)|
|Abstract:||Lung cancer is the leading cause of cancer death all over the world. The low 5-year survival rate (under 15%) has changed minimally in the last 25 years. Amongst different types of lung cancers, non-small cell lung carcinoma (NSCLC) types account 25-40%. To improve the survival of lung cancer patients, new therapeutic strategies are needed. The search for improved therapies has led to the investigation of agents that target novel pathways involved in tumor proliferation, invasion, survival and immune regulation. Cyclooxygenase-2 (COX-2) is one of the novel targets under evaluation for NSCLC therapy and chemoprevention. Although multiple genetic alterations are necessary for lung cancer invasion and metastasis, COX-2 may act as central element in orchestring these processes. COX-2 plays an important role in all aspects of tumor development and growth. It also plays a pivotal role in regulation of cytokines and immune responses in NSCLC patients. In this article, we review the experimental and clinical evidences on the possible link between COX and NSCLC.|
|Appears in Collections:||IJBB Vol.44(6) [December 2007]|
Files in This Item:
|IJBB 44(6) (2007) 419-428.pdf||249.19 kB||Adobe PDF||View/Open|
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.